Barinthus Biotherapeutics plc (BRNS) Financials

BRNS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 92.1 million 25.7 million
Dec. 31, 2025 98.2 million 23.9 million
Sept. 30, 2025 109.2 million 24.6 million
June 30, 2025 129.6 million 27.1 million

BRNS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -3.4 million 556000
Dec. 31, 2025 -4.2 million 696000
Sept. 30, 2025 -10.7 million -415000
June 30, 2025 -18.1 million -281000

BRNS Net Income

No data available :(

BRNS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 67.2 million - 9.0 million
Dec. 31, 2025 70.5 million - 9.3 million
Sept. 30, 2025 74.3 million - 11.6 million
June 30, 2025 86.3 million - 12.0 million

BRNS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 40.8 million
Dec. 31, 2025 40.5 million
Sept. 30, 2025 40.7 million
June 30, 2025 40.3 million

BRNS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 3.6 million 2.5 million -
Dec. 31, 2025 50 3.9 million 4.6 million -
Sept. 30, 2025 - 5.2 million 5.2 million -
June 30, 2025 32000 6.6 million 15.4 million -

BRNS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 854565
Dec. 31, 2025 - 907686
Sept. 30, 2025 - -
June 30, 2025 - 2.0 million

BRNS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

BRNS

Price: $0.66

52 week price:
0.51
2.92

Earnings Per Share: -1.29 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 26.6 million

Links: